RESUMO
BACKGROUND: Testosterone increases lean mass and may help to counter the changes in muscle architecture associated with sarcopenia. This study was designed to investigate the effects of testosterone replacement therapy on skeletal muscle architecture in intermediate-frail and frail elderly men. METHODS: A subgroup of 30 intermediate-frail and frail elderly men (65-89 years) with low to borderline-low testosterone levels were enrolled from a single-center randomized, double-blind placebo-controlled trial. Participants received either a transdermal testosterone (50 mg) or placebo gel daily for 6 months. Architecture (muscle thickness, fascicle length, and pennation angle) of the gastrocnemius medialis muscle was assessed by ultrasound imaging at baseline and after 6 months of treatment. RESULTS: Serum testosterone increased from 11.6 ± 3.5 to 18.0 ± 8.1 nmol/L by 10 days after randomization in the active group (but not the placebo group) and was maintained throughout the treatment period. Testosterone treatment resulted in a preservation of muscle thickness at 6 months while it decreased in the placebo group (effect size 1.4 [95% confidence interval = 0.3-2.5; p = .015]). There was no significant effect of treatment on fascicle length (effect size 1.9 mm [95% confidence interval = -1.2 to 5.0 mm; p = .22]) or pennation angle (effect size 1.2° [95% confidence interval = -1.3 to 3.7°; p = .32]). CONCLUSIONS: Testosterone replacement in intermediate-frail and frail elderly men is associated with preservation of muscle thickness. The results suggest that testosterone mitigates sarcopenia by improving muscle tissue to maintain a state of normality in aging men.
Assuntos
Músculo Esquelético/efeitos dos fármacos , Testosterona/farmacologia , Administração Cutânea , Idoso , Idoso de 80 Anos ou mais , Análise de Variância , Método Duplo-Cego , Idoso Fragilizado , Terapia de Reposição Hormonal , Humanos , Masculino , Músculo Esquelético/diagnóstico por imagem , Placebos , Sarcopenia/prevenção & controle , Testosterona/administração & dosagem , Testosterona/sangue , Resultado do Tratamento , UltrassonografiaRESUMO
Testosterone has been used in testicular and hypothalamo-pituitary diseases since the 1940s. There is growing interest in the use of testosterone in aging men, and this has stimulated research into the benefits of male hormone replacement. Testosterone treatment of men with hypogonadism might have beneficial effects on body composition, muscle strength, sexual function, and cognition. There are several modes of administration of the male hormone, with injectable testosterone esters and implanted testosterone pellets being the mainstay of treatment until recently. These preparations are increasingly being replaced by transdermal patches, gels, and long-acting parenteral preparations. Testosterone patches and gels are ideally for elderly men. Treatment with the male hormone is relatively safe, if patients are selected appropriately and monitored carefully. The most important adverse effects are on the prostate. In this review, we briefly discuss the indications, contraindications, and benefits of testosterone treatment. Further, we list the adverse effects, advantages, and disadvantages of various testosterone preparations in elderly men.
Assuntos
Androgênios/uso terapêutico , Hipogonadismo/tratamento farmacológico , Testosterona/uso terapêutico , Afeto/efeitos dos fármacos , Idoso , Envelhecimento/fisiologia , Androgênios/efeitos adversos , Densidade Óssea/efeitos dos fármacos , Cognição/efeitos dos fármacos , Contraindicações , Vias de Administração de Medicamentos , Sistemas de Liberação de Medicamentos , Humanos , Masculino , Disfunções Sexuais Fisiológicas/tratamento farmacológico , Testosterona/efeitos adversosRESUMO
Frailty is a clinical syndrome characterised by reduced physiologic reserve affecting multiple organ systems and is associated with increased risk of falls, fractures, hospitalisation and death. The impact of agerelated physical frailty on well-being and health in older men and the potential for prevention and treatment are beginning to be explored. Frailty is multifactorial with aging, comorbidity, sarcopenia, and endocrine immune dysfunction contributing to the condition. Falling testosterone levels with advancing age are associated with muscle loss (sarcopenia) and strength. Among the various therapeutic options being considered, testosterone supplementation offers promise due to its anabolic effects on muscle. In this review, we discuss the syndrome of frailty, its relationship with low testosterone and the effects of testosterone supplementation in healthy and unhealthy/frail older men on muscle mass, strength and physical performance.
Assuntos
Envelhecimento/fisiologia , Idoso Fragilizado , Força Muscular , Músculo Esquelético/fisiologia , Testosterona/deficiência , Idoso , Humanos , Masculino , Atividade Motora , Testosterona/fisiologiaRESUMO
We assessed the prevalence and 3-month change in glucose tolerance status in consecutive non-ST-elevation myocardial infarction (NSTEMI; European Society of Cardiology 2007 definition) patients (N=49; mean (S.D.) age 65 (11) years) admitted to a coronary care unit, without known diabetes. These patients underwent an oral glucose tolerance test (OGTT) 36-hour (median, IQR: 18-72) after admission and at 3 months. Undiagnosed abnormal glucose tolerance (AGT: impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or new diabetes) was common (61% at admission and 41% at 3 months, p<0.05) and the majority (approximately 3/4) had IGT. Glucose tolerance status improved in a higher proportion of patients than it worsened (31% vs. 8%, p=0.04). At 3 months, fasting glucose was unchanged but 2-hour OGTT glucose was lower (mean (S.D.): 8.5 (2.7) mmol/L vs. 7.7 (2.7) mmol/L, p=0.004). 'Stress hyperglycaemia' could explain higher admission glucose levels and this raises the question about the optimal timing of OGTT in relation to myocardial infarction. Newly diagnosed diabetes was present in approximately 10% of patients and this was not reliably detected by fasting plasma glucose. In NSTEMI patients OGTT is the only reliable strategy to identify subjects with IGT and diabetes.